Fabrication and characterization of silk fibroin-derived curcumin nanoparticles for cancer therapy by Gupta, Vishal et al.
© 2009 Gupta et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of Nanomedicine
International Journal of Nanomedicine 2009:4 115–122 115
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
O R I G I N A L   R e s e A R c h
Fabrication and characterization of silk  
fibroin-derived curcumin nanoparticles 
for cancer therapy
Vishal Gupta1 
Abraham Aseh1,3 
carmen N Ríos1 
Bharat B Aggarwal2 
Anshu B Mathur1
1Department of Plastic surgery; 
2Department of experimental 
Therapeutics, The University of Texas  
M.D.   Anderson cancer center, 
houston, TX, UsA; 3school of 
Pharmacy, Texas southern University, 
houston, TX, UsA
correspondence:   Anshu B Mathur 
Tissue Regeneration and Molecular 
cell engineering Labs (TRAMceL), 
Department of Plastic surgery,  
The University of Texas M.D.   Anderson 
cancer center, 1515 holcombe Blvd., 
Unit 602, Houston, TX 77230-1402, USA 
Tel +1 713 563 7568 
Fax +1 713 563 0231 
email amathur@mdanderson.org
Abstract: Biologically derived nanoparticles (100 nm) were fabricated for local and sustained 
therapeutic curcumin delivery to cancer cells. Silk fibroin (SF) and chitosan (CS) polymers were 
blended noncovalently to encapsulate curcumin in various proportions of SF and CS (75:25, 
50:50, and 25:75 SF:CS) or pure SF at two concentrations (0.1% w/v and 10% w/v) using the 
devised capillary-microdot technique. Curcumin-polymer conjugates were frozen, lyophilized, 
crystallized, suspended in phosphate-buffered saline for characterization, and tested for efficacy 
against breast cancer cells. All nanoparticle formulations except 0.1% w/v 50:50 SFCS were less 
than 100 nm in size as determined with the transmission electron microscopy. The entrapment 
and release of curcumin over eight days was highest for SF-derived nanoparticles as compared 
to all SFCS blends. The uptake and efficacy of SF-coated curcumin was significantly higher 
(p  0.001) than SFCS-coated curcumin in both low and high Her2/neu expressing breast cancer 
cells. Interestingly, the uptake of curcumin was highest for the high Her2/neu expressing breast 
cancer cells when delivered with a 10% w/v SF coating as compared to other formulations. 
In conclusion, SF-derived curcumin nanoparticles show higher efficacy against breast cancer 
cells and have the potential to treat in vivo breast tumors by local, sustained, and long-term 
therapeutic delivery as a biodegradable system.
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Introduction
Drug delivery to tumors is exacerbated by the toxicity to normal tissue in conjunction 
with low absorption at the tumor-site due to low retention of drugs by the tumor 
cells. The treatment of solid tumors such as pancreatic cancer, cervical cancer, and 
breast cancer with chemotherapeutic hydrophobic agents like ‘curcumin’ is limited 
by the lack of bioavailability and tissue specificity.1 Curcumin is a yellow polyphenol 
extracted from the rhizome of turmeric, which has strong activity as an anti-cancer 
agent as it inhibits proliferation of various tumor cells.2 Previously, curcumin was 
shown to suppress many tumorogenic pathways, including the Her2/neu pathway, in 
breast cancer cells.2,3
In order to enhance the bioavailability of curcumin, several approaches have been 
taken including the development of curcumin nanoparticles. Recent studies demon-
strated various formulations of curcumin nanoparticles using polymeric materials,4,5 
solid lipids,6 and liposomes.7–9 Although the use of liposomes reduced the toxicity, 
no tissue specificity is associated with the liposomes. Additionally, none of the above 
formulations were derived from natural polymers that would eliminate tissue toxicity 
while simultaneously increasing bioavailability.International Journal of Nanomedicine 2009:4 116
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Silk microspheres,10,11 nanolayers,12 and coatings on 
drug-loaded liposomes13,14 were previously used for the 
controlled release of various other drugs. Previously, silk 
fibroin (SF)-coated liposomal emodin was shown to have 
higher efficacy against breast cancer cells as compared to 
the uncoated liposomal emodin due to increased retention 
of emodin in the presence of SF.14 Loading the drug into 
liposomes and then coating them with SF produced particles 
that were larger in size than 100 nm.13
Therefore, this study was focused on harnessing the 
properties of the SF polymer as a drug delivery agent in 
order to increase the retention, efficacy, and bioavailability 
of curcumin by packaging it as a nanoparticle (100 nm). 
Moreover, SF was blended with chitosan (CS), since this 
blend was shown to be biocompatible, biodegradable, and 
supports the in vivo regeneration of tissues.15 Both SF and 
CS are derived from natural biopolymers. In this study, 
we investigated the fabrication and characterization (size, 
entrapment efficiency, and in vitro drug release) of SF- and 
CS-derived curcumin nanoparticles. Also, the intracellular 
uptake and efficacy of curcumin nanoparticles on low and 
high Her2/neu-expressing breast cancer cells was analyzed. 
Although curcumin was shown to suppress many tumorogenic 
pathways,2,3 this is the first time that curcumin nanoparticles 
have shown efficacy towards breast cancer cells.
Materials and methods
Preparation of silk fibroin  
and chitosan blends
Raw silk (Sao Paulo, Brazil) was generously donated by 
Dr Sam Hudson (North Carolina State University, Raleigh, 
NC) and high molecular weight chitosan (82.7% deacetylation) 
was obtained from Sigma-Aldrich (St. Louis, MO). 
Processing of SF and preparation of SFCS blends has been 
described previously.16 In brief, raw silk was degummed in 
0.25% (w/v) sodium carbonate and 0.25% (w/v) sodium 
dodecylsulfate (Sigma-Aldrich) for one hour at 100 °C and 
then dissolved in calcium nitrate tetrahydrate and methanol 
solution (molar ratio of 1:4:2 Ca:H2O:MeOH) at 65 °C. 
Chitosan was dissolved separately in a 2% acetic acid 
solution at the same concentration as silk fibroin solution 
and was mixed together to prepare a particular blend. For 
example, three parts of SF were mixed with one part of CS to 
prepare 75:25 SFCS. The SFCS solution was then dialyzed 
against ultrapure water for four days and filtered. The final 
solution was 10% w/v of SF or SFCS and diluted 100 times 
to make 0.1% w/v solutions.
Preparation of nanoparticles
Curcumin powder was weighed (1 mg) and suspended in 
100 µl of 25:75, 50:50, or 75:25 SFCS and SF only. These 
nanoparticles were prepared using the capillary microdot 
technique. The drug suspension was dispensed on glass slides 
via a microcapillary. The slides were then frozen overnight 
and lyophilized. Dry dots containing SFCS-coated curcumin 
nanoparticles were scraped off the slides and collected in a 
1.5 ml centrifuge tube. The SFCS coating was crystallized 
by suspending nanoparticles in 0.5 ml of 50:50 methanol 
and 1N sodium hydroxide solution (for SF coating, only 
methanol was used) for 15 minutes.13 The suspension was 
centrifuged at 8,960 g for 10 minutes, and the supernatant 
was removed. The pellet containing nanoparticles was rinsed 
with phosphate-buffered saline (PBS) twice to remove any 
remaining methanol and sodium hydroxide. PBS rinses were 
performed by adding 0.5 ml of PBS to the nanoparticles and 
centrifuging at 8,960 g for 10 minutes. After the second rinse, 
the SFCS-coated curcumin nanoparticles were suspended in 
PBS for further analysis.
size measurement using transmission 
electron microscopy (TeM)
SFCS-coated curcumin samples suspended in PBS were 
imaged using a JEM 1010 transmission electron microscope 
(TEM; JEOL USA Inc., Peabody, MA). Samples were placed 
on formver-coated and carbon-coated copper grids treated 
with poly-l-lysine for one hour. The samples were then 
blotted dry and imaged. The size of the nanoparticles from 
TEM images was measured using ImageJ software.
Curcumin entrapment efficiency  
and release
After collecting the nanoparticles from glass slides, the 
methanol/sodium hydroxide rinse and two subsequent 
PBS rinses (as defined above) were collected to calculate 
entrapment efficiency. The curcumin that was not entrapped 
(not coated with SFCS) was completely soluble in organic 
solvent and, hence, was collected in the methanol rinses. The 
amount of curcumin in the samples was measured by reading 
the absorbance at 424 nm using UV spectrophotometer 
(ThermoSpectronics, Rochester, NY) and calculated from 
the curcumin standard in ethanol.5 Similarly, for drug release, 
the nanoparticle suspension was centrifuged at 8,960 g for 
10 minutes and absorbance was measured in the supernatant. 
The pellet was again suspended in PBS for the next time point 
and kept in a 37 °C incubator shaker.International Journal of Nanomedicine 2009:4 117
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cell culture
Breast cancer cell lines MCF-7 (Her2-) and MDA-MB-453 
(Her2+) were obtained from American Type Culture Collection 
(ATCC, Manassas, VA). MCF-7 cells were cultured in 
Dulbecco Modified Eagle’s Medium with F-12 (Invitrogen, 
Grand Island, NY) and MDA-MB-453 cells in Leibovitz’s 
L-15 medium (ATCC). Both culture mediums were 
supplemented with 10% fetal bovine serum (Atlanta 
Biologicals, Lawrenceville, GA) and 1% antibiotic solution 
(Invitrogen).
Assay for intracellular uptake of curcumin
MCF-7 and MDA-MB-453 cells were seeded in 96-well 
plates (2,000 cells/well) and incubated overnight. SFCS- or 
SF-coated nanocurcumin was added to each well at a concen-
tration of 83.3 µg curcumin/well and incubated for four days. 
The nanoparticles contained in the medium were removed 
from the wells. Cells were lysed in 100 µl of dimethyl 
sulfoxide (DMSO; Fisher Scientific, Pittsburg, PA). A 50 µl 
cell lysis suspension was reserved for absorbance measure-
ment and the other 50 µl for fluorescence measurements 
using a VersaFluor fluorometer (Bio-Rad Laboratories, 
Hercules, CA). Two filters were utilized with 480 nm exci-
tation and 520 nm emission wavelengths. Since curcumin 
has auto-fluorescence properties,9 fluorescence assays were 
used in conjunction with absorbance to confirm the curcumin 
uptake measurements.
cell viability assay
To measure the efficacy of nanocurcumin on MCF-7 and 
MDA-MB-453, the cells were seeded in 96-well plates 
(2,000 cells/well) and incubated overnight. Nanocurcumin 
coated with SFCS or SF was added to each well at a concen-
tration of 83.3 µg curcumin/well and incubated for four days. 
The nanoparticles contained in the medium were removed 
from the wells and a CellQuanti-MTT cell viability assay kit 
(BioAssay Systems, Hayward, CA) was used to determine 
the viability of cells remaining in each well. Briefly, 80 µl of 
culture medium and 15 µl of MTT reagent were added to each 
well and incubated for four hours. Then, MTT solubilization 
solution (100 µl) was added to each well, and the plates were 
placed on a shaker for one hour. The absorbance readings were 
taken at 570 nm using a MRX Microplate Reader (Dynex 
Technologies, Guernsey, Channel Islands, UK).
statistical analysis
All data analysis was performed using SigmaStat statistical 
program. One-way analysis of variance (ANOVA) was used 
with post-hoc Tukey test for pair-wise comparisons. All data 
was represented as mean ± standard error of mean (SEM) 
and level of significance was chosen as p  0.05.
Results
Nanoparticle size measurement
SF- or SFCS-encapsulated curcumin nanoparticles fabri-
cated with either 0.1% w/v or 10% w/v SF or SFCS were 
imaged using TEM to characterize the size (Figure 1). Size 
measurements of curcumin encapsulated particles showed 
that all formulations resulted in particles of sizes less than 
100 nm except for 0.1% w/v 50:50 SFCS (130 ± 4.2 nm) 
(Figure 2). Particle size of curcumin coated with 0.1% 
w/v SF was significantly lower than 0.1% w/v 50:50 SFCS 
(p  0.001) and higher than 0.1% w/v 25:75 SFCS and 0.1% 
w/v 75:25 SFCS (p  0.001) fabricated particles. The particle 
size for 10% w/v 75:25 SFCS was significantly higher than 
10% w/v SF, 10% w/v 25:75 SFCS, and 10% w/v 50:50 
SFCS (p  0.001).
Although there are differences in the size of the 
nanoparticles between high and low concentrations of SF 
content, no specific trend was noted. The size of particles 
coated with 0.1% w/v SF and 0.1% w/v 50:50 SFCS was 
significantly higher than 10% w/v SF and 10% w/v 50:50 
SFCS (p  0.001). However, 0.1% w/v 25:75 SFCS-coated 
nanoparticles were smaller than 10% w/v 25:75 SFCS-coated 
particles (p  0.05). The size of SF and SFCS control parti-
cles (without drug) were also measured (data not shown) and 
found to be comparable with curcumin-loaded particles.
Curcumin entrapment efficiency
The entrapment of curcumin was more than 96% for 
SF-coated nanoparticles for both 0.1% and 10% SF. The 
entrapment efficacy decreased to 64%–73% for SFCS coated 
nanoparticles regardless of concentration of SF and CS 
(Figure 3). Curcumin entrapment was significantly higher 
for 0.1% w/v SF (p  0.01) and 10% w/v SF (p  0.05) 
compared to all SFCS blends.
In vitro curcumin release 
from nanoparticles
The curcumin release profiles for both 0.1% w/v and 10% 
w/v preparations showed an initial burst release (up to 
two days) of curcumin from both SF and SFCS blends 
(Figure 4). However, curcumin release from SFCS blends 
did not increase any further over eight days. The high and 
low concentrations of SF-coated curcumin nanoparticles 
consistently released curcumin in large amounts over eight International Journal of Nanomedicine 2009:4 118
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days. As shown in Figure 4, cumulative release of curcumin 
from SF-coated nanoparticles at day 8 was significantly 
higher than all other SFCS-blend nanoparticles (p  0.05 
for 0.1% w/v and p  0.001 for 10% w/v solutions). Also, 
at day 8 the release from 10% SF was significantly greater 
than 0.1% w/v SF (p  0.001).
The release of drugs from polymers has been previously 
modeled by the power law equation.17
	
M
M
kt
t n
∞
= 	 (1)
The ratio of Mt and M, the amounts of drug at any time t and 
at infinite time, respectively, was plotted against time, t, result-
ing in the derivation of parameters k and n, which are dependent 
upon the composition/structure of the coating and release 
mechanism, respectively. Table 1 shows the values of n and k 
for all the nanoparticle formulations. The parameter n ranged 
from 0.15 to 0.55 for the various nanoparticle formulations 
in Table 1, suggesting a diffusion-based release mechanism 
of curcumin from the nanoparticles.17 Based on k values, the 
amount of drug released was significantly higher for 10% w/v 
SF as compared to 0.1% w/v SF and all other SFCS blends 
(p  0.001).
Intracellular uptake of curcumin
The absorbance measurements of intracellular uptake of 
curcumin by Her2/neu low- and high-expressing breast 
cancer cells show that the curcumin uptake was highest 
from SF-coated nanoparticles as compared to the respective 
0.1% w/v and 10% w/v SFCS blend groups (Figure 5). These 
differences were similar for both MCF-7 and MDA-MB-453 
cells. The fluorescence measurements also showed similar 
uptake data as compared to the absorbance measurements 
(Figure 6). Interestingly, curcumin uptake by MDA-MB-453 
cells was higher from 10% w/v SF-coated nanoparticles 
than 0.1% w/v SF-coated nanoparticles as measured by both 
absorbance and fluorescence.
Figure 1 TeM images of the curcumin nanoparticle formulations.   All blends of sFcs and sF alone were made of 10% w/v solution in these TeM images.
Abbreviations: SF, silk fibroin; SFCS, silk fibroin and chitosan; TEM, transmission electron microscopy.International Journal of Nanomedicine 2009:4 119
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Curcumin nanoparticle efficacy against 
breast cancer cells
The efficacy of curcumin nanoparticle formulations 
was measured for both MCF-7 and MDA-MB-453 cells 
using the MTT assay (Figure 7). The number of cells in 
the control samples (no nanoparticles) increased from 
2,000 (initial density) to 3,563 ± 215 (MCF-7) and 
3,267 ± 864 (MDA-MB-453) over a period of four days. 
Exposure of 0.1% w/v SF and 10% w/v SF nanocurcumin 
to MCF-7 and MDA-MB-453 cells significantly decreased 
the number of viable cells compared to controls (p  0.01). 
On the other hand, there was no difference in cell viability 
for the SFCS blends as compared to the control group. Also, 
the efficacy of 0.1% w/v SF was higher than 0.1% w/v 25:75 
SFCS for MCF-7 cells (p  0.01) and 0.1% w/v 50:50 SFCS 
for MDA-MB-453 cells (p  0.01). Similarly, 10% w/v SF 
nanocurcumin had significantly higher efficacy against both 
types of breast cancer cells as compared to 10% w/v 25:75 
SFCS and 10% w/v 50:50 SFCS (p  0.05).
Discussion
SF- and SFCS-coated curcumin nanoparticles (100 nm) 
were fabricated and characterized. SF-coated nanoparticles 
showed the highest entrapment and release of curcumin, 
which resulted in higher intracellular uptake and efficacy 
Table 1 The exponent ‘n’ and constant ‘k’ values from the power 
law equation for various nanoparticle formulations.
Coatings n k (×10-4 per/day)
0.1% sF 0.55 ± 0.10 0.9 ± 0.1
0.1% 25:75 sFcs 0.25 ± 0.05 1.0 ± 0.4
0.1% 50:50 sFcs 0.17 ± 0.05 1.0 ± 0.5
0.1% 75:25 sFcs 0.15 ± 0.05 0.8 ± 0.1
10% sF 0.32 ± 0.03 3.0 ± 0.0
10% 25:75 sFcs 0.28 ± 0.18 0.5 ± 0.07
10% 50:50 sFcs 0.48 ± 0.17 0.6 ± 0.06
10% 75:25 sFcs 0.45 ± 0.08 0.6 ± 0.2
Abbreviations: SF, silk fibroin; SFCS, silk fibroin and chitosan.
Figure 2 curcumin nanoparticle sizes as measured from  TeM images. Between 22 to 50 
nanoparticles were measured from TeM images for each formulation. *p  0.001 vs 
0.1% sF, †p  0.001 vs 0.1% 25:75 sFcs, φp  0.05 vs 10% 25:75 sFcs, ‡p  0.001 vs 
0.1% 50:50 sFcs, #p  0.001 vs 10% 75:25 sFcs.
Abbreviations: sF, silk fibroin; SFCS, silk fibroin and chitosan; TEM, transmission 
electron microscopy.
Figure 3 curcumin entrapment within nanoparticles (n = 3). *p  0.01 vs 0.1% sF, 
†p  0.001 vs 0.1% sF, ‡p  0.05 vs 10% sF, φp  0.01 vs 10% sF.
Abbreviations: SF, silk fibroin.
Figure 4 cumulative curcumin release from nanoparticles over the period of eight 
days (n = 3). All blends of sFcs and sF alone were made of (a) 0.1% solution and 
(b) 10% solution.
Abbreviations: sF, silk fibroin; SFCS, silk fibroin and chitosan.International Journal of Nanomedicine 2009:4 120
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towards breast cancer cells. To our knowledge, only two other 
studies reported the fabrication of curcumin nanoparticles 
of less than 100 nm,4,5 however neither was manufactured 
from biologically derived regenerative biomaterials such as 
SF and CS.15
Curcumin entrapment was higher in SF-coated nanopar-
ticles compared to all other SFCS blend formulations. The 
introduction of CS in the nanoparticle formulation of SF 
resulted in an increase of its hydrophilic character since CS is 
a water-carrying glucosamine molecule. Curcumin is a hydro-
phobic drug and hence the presence of CS with SF may have 
resulted in reducing the entrapment efficiency of curcumin. 
A very small amount (0.09–0.13 µg) of curcumin was released 
from the SFCS-coated nanoparticles as compared to SF-coated 
nanoparticles (0.32–0.68 µg) over eight days, which may have 
resulted from lower initial entrapment. The curcumin entrap-
ment was initially low in SFCS coated nanoparticles resulting 
in the overall reduced release. Due to lower entrapment, the 
diffusion gradient of curcumin release from SFCS nanopar-
ticles was also less as compared to SF-encapsulated curcumin 
nanoparticles. Previously, drug release from SF-coated lipo-
somes was also found to be diffusion-controlled.13
The intracellular uptake of curcumin was also highest for 
the SF-coated nanoparticles compared to SFCS blends, which 
followed the curcumin entrapment and release data. Other than 
the nanoparticle size, the effect of concentration (10% w/v 
vs 0.1% w/v) was only evident in the intracellular uptake 
of curcumin by MDA-MD-453 cells. The curcumin uptake 
was significantly higher from 10% w/v SF than 0.1% w/v 
SF nanoparticles as measured by both absorbance and fluo-
rescence assays. The effect of SF on the efficacy of breast 
cancer cells was previously studied with the SF coating of 
emodin-loaded liposomes. The SF coating of emodin-loaded 
liposomes was shown to have higher efficacy in Her2/neu 
high-expressing breast cancer cells (MDA-MB-453).14 Due 
to higher retention of emodin in the Her2/neu high expressing 
breast cancer cells, more signal transduction pathways were 
affected resulting in higher efficacy as compared to uncoated 
emodin-loaded liposomes. In this study, the higher SF 
content (10% w/v) resulted in higher uptake and intracellular 
residence time for curcumin, which also increased efficacy 
against breast cancer cells. While the SF coating of emodin in 
the study by Cheema and colleagues was 0.1% w/v SF,14 we 
found that increasing the SF coating amount from 0.1% w/v 
to 10% w/v increased the curcumin entrapment and cellular 
uptake significantly, thereby affecting efficacy.
The efficacy of SF-coated nanocurcumin on breast 
cancer cells was significantly higher than SFCS-coated 
Figure 5 Intracellular uptake of curcumin by breast cancer cells as measured 
by absorbance assay after exposure to curcumin nanoparticles for four days (n = 3). 
(a) MCF-7, *p  0.01 vs 0.1% sF, †p  0.001 vs 10% sF (b) MDA-MB-453, ‡p  0.001 
vs 0.1% sF, φp  0.001 vs 10% sF, #p  0.01 vs 10% sF.
Abbreviation: SF, silk fibroin.
Figure 6 Intracellular uptake of curcumin by breast cancer cells as measured by 
fluorescence assay after exposure to curcumin nanoparticles for four days (n = 3). 
(a) MCF-7, *p  0.01 vs 0.1% sF, †p  0.05 vs 10% sF (b) MDA-MB-453, ‡p  0.001 
vs 0.1% sF, φp  0.001 vs 10% sF.
Abbreviation: SF, silk fibroin.International Journal of Nanomedicine 2009:4 121
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nanocurcumin. Efficacy data followed the curcumin 
uptake data, which showed high uptake of curcumin from 
SF-coated nanoparticles and hence reduced viability of 
Her2/neu high-expressing breast cancer cells. Previously, 
curcumin was shown to suppress Her2 and nuclear factor-κβ 
pathways in breast cancer cells.3,18 Interestingly, Her2/neu 
low-expressing MCF-7 breast cancer cells also undergo 
apoptosis upon exposure to curcumin nanoparticles. Since 
curcumin is known to act through many pathways in various 
cancer cells,2 there may be a down modulation of more than 
one pathway in breast cancer cells due to longer availability 
of curcumin via SF nanoparticles.14
One of the limitations of this study was the minor drug 
loss during the transfer of nanoparticles from the glass 
slides. Although the use of the same procedure to transfer 
the nanoparticles should have minimized this effect when 
comparing groups. It was difficult to calculate the amounts 
of drug loss because entrapment efficiencies were calculated 
based on the un-entrapped drug during methanol/sodium 
hydroxide wash and the initial amount of drug used to 
mix with the SF or SFCS blends. However, it was evident 
from intracellular uptake and efficacy data that SF-coated 
nanoparticles entrapped and released the most drug as 
compared to other SFCS blend-coated nanoparticles. When 
considering the hydrophobic nature of curcumin with respect 
to the hydrophilic nature of chitosan, as mentioned earlier, 
this conclusion is logical. Another limitation of the study was 
the release of very small amounts of curcumin over time, 
which may be related to the medium (PBS) into which the 
release study was conducted. It is possible that the amount 
of released curcumin would be affected under serum or 
plasma conditions.
The treatment of several cancers in the future will be influ-
enced by the ability of scientists to produce drug formulations 
that have high drug availability at tumor sites, sustained and 
long-term release, and minimal to no toxicity to healthy tis-
sues. Biologically derived nanoparticles offer great promise 
in this regard due to the minimization of adverse effects while 
increasing the efficacy of the entrapped drug.
In conclusion, the SF- and SFCS-coated curcumin 
nanoparticles were fabricated using a novel technique. The 
size of the nanoparticles that showed high curcumin entrap-
ment and efficacy towards breast cancer cells was less than 
100 nm. Nanoparticles of curcumin encapsulated with pure 
SF showed the highest curcumin entrapment, release, intra-
cellular uptake, and efficacy towards breast cancer cells as 
compared to SFCS curcumin nanoparticles. The coating of 
SF can be used for nanoparticle preparation of numerous 
drugs or therapeutics for localized and long-term release for 
the treatment of cancer and many other diseases.
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